All Year, 24/7 - The Big Business, Brands, Enterprises, Institutions, Communities and Groups

Hardy Diagnostics Releases HardyCHROM™ Candida + auris

PRESS RELEASE - Oct 20, 2021 03:00 PDT

Medium offers easy-to-read chromogenic and fluorogenic results

- Oct 20, 2021 03:00 PDT


Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective isolation and differential identification of Candida species. This medium allows for the identification of C. albicans, C. tropicalis, C. krusei, and the presumptive identification of C. glabrata. Colonies of C. auris will appear white with a characteristic teal to teal-green "bullseye" center. Additionally, C. auris is also differentiated from other Candida species by a unique fluorogenic reaction under UV light.

C. auris is an emerging pathogen that represents a serious multi-drug resistant (MDR) global threat. C. auris may persistently colonize the skin and hospital environment, making its transmission within and between healthcare settings more difficult to control.(1) C. auris results in a wide range of mortality rates depending on the patient's overall condition, underlying disease, geographic region, access to medical care, and age.(1)

HardyCHROM™ Candida + auris can be used in conjunctions with Rapid Trehalose Broth or GlabrataQuick to aid in the identification of C. glabrata.  

Find more information on HardyCHROM™ Candida + auris here.

Media questions can be directed to Megan Roesner at roesnerm@hardydiagnostics.com

  1. Rossato, L. and A.L. Colombo. 2018. Candida auris: What Have We Learned About its Mechanisms of Pathogenicity? Frontiers in Micro.

Source: Hardy Diagnostics


About


Tags:

PRESS CONTACT


Post By Admin